Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
- PMID: 39814982
- DOI: 10.1038/s41581-024-00926-x
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Erratum in
-
Publisher Correction: Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.Nat Rev Nephrol. 2025 May;21(5):355. doi: 10.1038/s41581-025-00939-0. Nat Rev Nephrol. 2025. PMID: 39905262 No abstract available.
Abstract
X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert. Historically, these patients were treated with frequent doses of oral phosphate supplements and active vitamin D, which was of limited efficiency and associated with adverse effects. However, the management of XLH has evolved in the past few years owing to the availability of burosumab, a fully humanized monoclonal antibody that neutralizes circulating FGF23. Here, we provide updated clinical practice recommendations for the diagnosis and management of XLH to improve outcomes and quality of life in these patients.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: J.B. and L.S. receive support for research and consultancy from Kyowa Kirin. A.L., M.B.D., L.R. and C.C. receive research support from Kyowa Kirin. D.H. receives research support and speaker and consultant fees from Kyowa Kirin. The institution of A.L. (AP-HP) receives her speaker and consultant fees from Kyowa Kirin. G.A. receives speaker and consultant fees from Kyowa Kirin. F.E., E.L., P.K., K.B., D.S., M.L.B. and K.B. receive consultation fees from Kyowa Kirin. All other authors declare no competing interests.
References
-
- Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M. & Insogna, K. L. A clinician’s guide to X-linked hypophosphatemia. J. Bone Min. Res. 26, 1381–1388 (2011). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
